<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04264975</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0608</org_study_id>
    <nct_id>NCT04264975</nct_id>
  </id_info>
  <brief_title>Utilization of Microbiome as Biomarkers and Therapeutics in Immuno-Oncology</brief_title>
  <official_title>Utilization of Microbiome as Biomarkers and Therapeutics in Immuno-Oncology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, single-center, non-randomized clinical trial on utilization of&#xD;
      microbiome as biomarkers and therapeutics in immuno-oncology.&#xD;
&#xD;
      This research consists of two parts:&#xD;
&#xD;
      part 1: development of microbiome biomarkers for immuno-oncology part 2: proof-of-concept&#xD;
      trial on the fecal microbiota transplantation in patients who are being treated with&#xD;
      immunotherapy for advanced solid tumor&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an open label, single-center, non-randomized clinical trial on utilization of microbiome as biomarkers and therapeutics in immuno-oncology.&#xD;
This research consists of two parts:&#xD;
part 1: development of microbiome biomarkers for immuno-oncology part 2: proof-of-concept trial on the fecal microbiota transplantation in patients who are being treated with immunotherapy for advanced solid tumor</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>5 years</time_frame>
    <description>the proportion of patients who have a partial or complete response to therapy per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1 or immune RECIST(iRECIST)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Solid Carcinoma</condition>
  <arm_group>
    <arm_group_label>Fecal microbiota transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal microbiota transplantation in patients who have advanced solid cancer with primary (group 1) or secondary resistance (group 2) to immuno-oncology</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>fecal microbiota transplantation</intervention_name>
    <description>Fecal microbiota transplantation (FMT) is the administration of a solution of fecal matter from a donor into the intestinal tract of a recipient in order to directly change the recipient's microbial composition and confer a health benefit</description>
    <arm_group_label>Fecal microbiota transplantation</arm_group_label>
    <other_name>FMT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Part 1: development of microbiome biomarkers&#xD;
&#xD;
        &lt;Inclusion Criteria:&gt; 1.Patients with pathologically confirmed solid cancer who are being&#xD;
        treated with immunotherapy or are going to receive immunotherapy&#xD;
&#xD;
          1. Age ≥ 19 years old&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group performance status 0-2&#xD;
&#xD;
          3. Measurable or evaluable lesion(s) according to Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST) v1.1&#xD;
&#xD;
        &lt;Exclusion Criteria&gt;&#xD;
&#xD;
          1. A history of other cancers requiring treatment within the recent 3 years (excepting&#xD;
             treated basal or squamous cell carcinoma of the skin, superficial bladder cancer, or&#xD;
             carcinoma in situ of the prostate, cervix, breast, or stomach)&#xD;
&#xD;
          2. A history of active primary immunodeficiency&#xD;
&#xD;
          3. Active infection including tuberculosis or Human Immunodeficiency Virus (HIV)&#xD;
&#xD;
          4. Autoimmune disease (excepting type 1 diabetes mellitus, hypothyroidism requiring&#xD;
             hormone replacement therapy only, skin disease not requiring systemic therapy (such as&#xD;
             vitiligo, psoriasis or alopecia)&#xD;
&#xD;
          5. Patients who are receiving immunosuppressive medications (excepting topical steroids,&#xD;
             systemic steroid ≤10 mg/day prednisone or equivalents, or a brief course of steroids&#xD;
             for prophylaxis (e.g., hypersensitivity reaction)&#xD;
&#xD;
             --------------------------------------------------------------------------------------&#xD;
             ------&#xD;
&#xD;
        part 2: proof-of-concept trial on the fecal microbiota transplantation in patients who are&#xD;
        being treated with immunotherapy for solid cancers&#xD;
&#xD;
        &lt;Inclusion Criteria for donors&gt;&#xD;
&#xD;
          1. Patients who have partial or complete response to immunotherapy at the time of stool&#xD;
             donation&#xD;
&#xD;
          2. No history of exposure to HIV or hepatitis virus within the previous 12 months&#xD;
&#xD;
          3. No history of international travel within previous 6 months to areas of high risk of&#xD;
             travelers' diarrhea&#xD;
&#xD;
          4. No current communicable disease&#xD;
&#xD;
          5. No household members with active gastrointestinal infection&#xD;
&#xD;
          6. No history of inflammatory bowel disease&#xD;
&#xD;
          7. No recent intake of potential allergenic foods that are known to cause&#xD;
             hypersensitivity in a recipient (such as peanut)&#xD;
&#xD;
        &lt;Inclusion criteria for recipients&gt;&#xD;
&#xD;
          1. Patients without contraindications for colonoscopy such as suspected bowel&#xD;
             perforation, acute diverticulitis, or fulminant colitis&#xD;
&#xD;
          2. Patients who have disease progression to immunotherapy as one of the following two&#xD;
             patterns:&#xD;
&#xD;
        2-1) Patients who have disease progression due to primary resistance to immunotherapy&#xD;
&#xD;
        2-2) Patients who have disease progression following disease stabilization due to secondary&#xD;
        resistance to immunotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sook Ryun Park, M.D, Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center, Ulsan University of College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sook Ryun Park, M.D, Ph D</last_name>
    <phone>+82-2-3010-3210</phone>
    <email>srpark@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sook Ryun Park, M.D, Ph D</last_name>
      <phone>+82-2-3010-3206</phone>
      <email>srpark@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 2, 2020</study_first_submitted>
  <study_first_submitted_qc>February 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Sook Ryun Park</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>immuno-oncology</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>biomarker</keyword>
  <keyword>fecal microbiota transplantation (FMT)</keyword>
  <keyword>microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD sharing is not planned.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

